Browsing Cancer Therapeutics by author "Klampatsa, Astero"
Now showing items 1-16 of 16
-
Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.
Klampatsa, A; Leibowitz, MS; Sun, J; Liousia, M; Arguiri, E; et al. (CELL PRESS, 2020-09-25)The therapeutic efficacy of adoptive transfer of T cells transduced with chimeric antigen receptors (CARs) has been limited in the treatment of solid cancers, partly due to tumor antigen heterogeneity. Overcoming lack of ... -
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy.
Hawkins, ER; D'Souza, RR; Klampatsa, A (DOVE MEDICAL PRESS LTD, 2021-01-01)Chimeric antigen receptor (CAR) T-cell therapy engineers T-cells to express a synthetic receptor which redirects effector function to the tumor, to improve efficacy and reduce toxicities associated with conventional ... -
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.
Thayaparan, T; Petrovic, RM; Achkova, DY; Zabinski, T; Davies, DM; et al. (TAYLOR & FRANCIS INC, 2017-12-02)Mesothelioma is an incurable cancer for which effective therapies are required. Aberrant MET expression is prevalent in mesothelioma, although targeting using small molecule-based therapeutics has proven disappointing. ... -
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).
Klampatsa, A; Haas, AR; Moon, EK; Albelda, SM (MDPI, 2017-09-01)Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes ... -
Current Advances in CAR T Cell Therapy for Malignant Mesothelioma.
Klampatsa, A; Albelda, SM (Scientific Archives LLC, 2020-06-22)Malignant mesothelioma is a relatively rare malignancy arising in the body's serosal surfaces, with malignant pleural mesothelioma (MPM) being the most common type. It is characterized by local spread within the thorax, ... -
Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma.
Bughda, R; Dimou, P; D'Souza, RR; Klampatsa, A (DOVE MEDICAL PRESS LTD, 2021-01-01)Fibroblast activation protein (FAP) is a membrane protease that is highly expressed by cancer-associated fibroblasts (CAFs). FAP can modulate the tumor microenvironment (TME) by remodeling the extracellular matrix (ECM), ... -
Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.
O'Brien, SM; Klampatsa, A; Thompson, JC; Martinez, MC; Hwang, W-T; et al. (AMER ASSOC CANCER RESEARCH, 2019-06-01)Cancer progression is marked by dysfunctional tumor-infiltrating lymphocytes (TIL) with high inhibitory receptor (IR) expression. Because IR blockade has led to clinical responses in some patients with non-small cell lung ... -
Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Klampatsa, A; Achkova, DY; Davies, DM; Parente-Pereira, AC; Woodman, N; et al. (ELSEVIER IRELAND LTD, 2017-05-01)Malignant mesothelioma remains an incurable cancer. We demonstrated that mesotheliomas expressed EGFR (79.2%), ErbB4 (49.0%) and HER2 (6.3%), but lacked ErbB3. At least one ErbB family member was expressed in 88% of tumors. ... -
Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy.
Davis, RW; Snyder, E; Miller, J; Carter, S; Houser, C; et al. (WILEY, 2019-01-01)Inflammatory cells, most especially neutrophils, can be a necessary component of the antitumor activity occurring after administration of photodynamic therapy. Generation of neutrophil responses has been suggested to be ... -
Mesothelin-targeted CAR-T cell therapy for solid tumors.
Klampatsa, A; Dimou, V; Albelda, SM (TAYLOR & FRANCIS LTD, 2021-04-03)Introduction: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the body's mesothelial surfaces, but significantly overexpressed in a broad range of solid tumors. For this reason, MSLN has emerged ... -
Overcoming tumor antigen heterogeneity in CAR-T cell therapy for malignant mesothelioma (MM)
D'Souza, RR; Dimou, P; Bughda, R; Hawkins, E; Babe, CL; et al. (OAE PUBLISHING INC, 2022-01-01)<jats:p>Malignant mesothelioma (MM) is a rare, aggressive solid tumor with limited therapeutic options and poor therapeutic response. The role of immunotherapy in MM is now well established and therapeutic options, such ... -
Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.
Klampatsa, A; O'Brien, SM; Thompson, JC; Rao, AS; Stadanlick, JE; et al. (TAYLOR & FRANCIS INC, 2019-09-02)Given the growing interest and promising preliminary results of immunotherapy in malignant pleural mesothelioma (MPM), it has become important to more fully understand the immune landscape in this tumor. This may be ... -
Precision-Cut Tumor Slices (PCTS) as an Ex Vivo Model in Immunotherapy Research.
Dimou, P; Trivedi, S; Liousia, M; D'Souza, RR; Klampatsa, A (MDPI, 2022-04-06)Precision-cut tumor slices (PCTS) have recently emerged as important ex vivo human tumor models, offering the opportunity to study individual patient responses to targeted immunotherapies, including CAR-T cell therapies. ... -
A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.
Davis, RW; Papasavvas, E; Klampatsa, A; Putt, M; Montaner, LJ; et al. (WILEY, 2018-07-01)OBJECTIVE: Inflammation is a well-known consequence of surgery. Although surgical debulking of tumor is beneficial to patients, the onset of inflammation in injured tissue may impede the success of adjuvant therapies. One ... -
Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy.
Davis, RW; Klampatsa, A; Cramer, GM; Kim, MM; Miller, JM; et al. (AMER ASSOC CANCER RESEARCH, 2023-09-11)UNLABELLED: Surgical cytoreduction for patients with malignant pleural mesothelioma (MPM) is used for selected patients as a part of multi-modality management strategy. Our group has previously described the clinical use ... -
Transcriptomic analysis-guided assessment of precision-cut tumor slices (PCTS) as an ex-vivo tool in cancer research.
Trivedi, S; Tilsed, C; Liousia, M; Brody, RM; Rajasekaran, K; et al. (NATURE PORTFOLIO, 2024-05-14)With cancer immunotherapy and precision medicine dynamically evolving, there is greater need for pre-clinical models that can better replicate the intact tumor and its complex tumor microenvironment (TME). Precision-cut ...